Related Experiment Video

Updated: May 15, 2026

Measuring the Confluence of iPSCs Using an Automated Imaging System
11:39

Measuring the Confluence of iPSCs Using an Automated Imaging System

Published on: June 10, 2020

Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative

Jennifer Walsh1, Simon Mills

  • 1Jenny Walsh Consulting Ltd, BioCity, Nottingham, UK. jenny@jennywalshconsulting.com

Therapeutic Delivery
|January 18, 2013
PubMed

Insights

The European Paediatric Formulation Initiative (EuPFI) conference focused on developing better medicines and administration devices for children. Experts shared practical solutions and addressed challenges in pediatric drug development.

Area of Science:

  • Pediatric Pharmacology
  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • The 4th annual European Paediatric Formulation Initiative (EuPFI) conference convened to address the unique challenges in pediatric drug formulation and delivery.
  • The event highlighted the critical need for age-appropriate medicines and administration devices tailored to pediatric patient populations.
  • It brought together European and US experts to discuss advancements and opportunities in the field.

Framework:

  • The conference featured a comprehensive program including plenary talks, focus sessions, case studies, and poster presentations.
  • Key work streams covered extemporaneous preparations, excipients, pediatric administration devices, taste masking, taste assessment, and age-appropriate formulations.
  • The agenda was designed to provide practical insights and illustrate solutions for common hurdles in pediatric drug development.

Implementation:

  • Discussions centered on emerging practical applications and remedies employed by pediatric drug development teams.
  • The focus was on overcoming specific challenges encountered when formulating medicines for children.
  • Sharing of best practices and innovative approaches was a core component of the conference.

Implications:

  • The conference report summarizes key lectures and presentations, offering a valuable resource for researchers and industry professionals.
  • It underscores the collaborative effort required to advance the development of safe and effective pediatric medicines.
  • The insights shared aim to improve the formulation and administration of drugs for pediatric patients, enhancing therapeutic outcomes.

More Related Videos

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...